Literature DB >> 6156221

In vitro effects of antiprotozoan drugs and immune serum on Pneumocystis carinii.

E L Pesanti.   

Abstract

The in vitro survival of Pneumocystis carinii isolated from the lungs of rats with glucocorticoid-induced pneumocystosis has been evaluated by quantitation of uptake of vital dyes by the organisms after exposure to a variety of drugs, immune serum, and medium enriched with macrophage lysosomal enzyme. On the basis of these tests, it appears that pentamidine and chloroquine are directly lethal to the organisms, but that suramin, trimethoprim, and sulfamethoxazole are not. Neither immune serum supplemented with complement and lysozyme nor the supernatant of phagocytosing macrophages appeared to affect the viability of the organisms. Inhibitors of glucose uptake and metabolism appeared to kill Pneumocystis, but neither cycloheximide nor iododeoxyuridine was effective.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6156221     DOI: 10.1093/infdis/141.6.775

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia.

Authors:  J P Monk; P Benfield
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 2.  Pneumocystis carinii: the continuing enigma.

Authors:  P S Hasleton; A Curry
Journal:  Thorax       Date:  1982-07       Impact factor: 9.139

3.  In vitro activities of acridone alkaloids against Pneumocystis carinii.

Authors:  S F Queener; H Fujioka; Y Nishiyama; H Furukawa; M S Bartlett; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  Does cyclosporin A adversely affect Pneumocystis carinii infection?

Authors:  R J McGonigle; M Beaman; J Stone; J Young; J Michael; D Adu
Journal:  Postgrad Med J       Date:  1988-09       Impact factor: 2.401

Review 5.  Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia.

Authors:  K L Goa; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.

Authors:  J C Comley; R J Mullin; L A Wolfe; M H Hanlon; R Ferone
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Metabolic and synthetic activities of Pneumocystis carinii in vitro.

Authors:  E L Pesanti; C Cox
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  Phospholipid profile of Pneumocystis carinii and its interaction with alveolar type II epithelial cells.

Authors:  E L Pesanti
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

9.  Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.

Authors:  M T Cushion; D Stanforth; M J Linke; P D Walzer
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.